Vulinacimab
Based on 1 Customer Validation
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.40%
- No. CAS: 2250342-36-8
- Peso molecular:145.28 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
VEGFR-2 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male; subcutaneously implanted A549 cells into both side flank to establish a xenograft model)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; twice a week for 6 weeks
-
Result:Had no antitumor activity in monotherapy.
Exhibited potent antitumor activity when used in combination with HLX07.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized VEGFR-2 Protein, Human (HEK293, His, HY-P70552) can bind Vulinacimab. The EC50 for this effect is 4.326 ng/mL.
Chemical Information
-
No. CAS 2250342-36-8
-
Appearance Liquid
-
Peso molecular 145.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Vulinacimab]
-
Synonyms
HLX-06
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)